Amgen Inc. Deferred Income Tax Liabilities, Net
Amgen Inc. (AMGN) had Deferred Income Tax Liabilities, Net of $1.30 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-05
- 2026-06-30: Deferred Income Tax Liabilities, Net $1.30B.
- 2026-03-31: Deferred Income Tax Liabilities, Net $1.34B.
- 2025-12-31: Deferred Income Tax Liabilities, Net $1.37B.
- 2025-09-30: Deferred Income Tax Liabilities, Net $1.46B.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $1.30B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.34B 10-Q · filed 2026-05-01 |
| 2025-12-31 | $1.37B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.46B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.39B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.51B 10-Q · filed 2025-05-02 |
| 2024-12-31 | $1.62B 10-K · filed 2026-02-13 |
| 2024-09-30 | $1.71B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.78B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.86B 10-Q · filed 2024-05-03 |
| 2023-12-31 | $2.35B 10-K · filed 2025-02-14 |
| 2022-12-31 | $11.00M 10-K · filed 2024-02-14 |
| 2020-09-30 | $210.00M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $259.00M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $427.00M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $606.00M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |